Originally published as JCO Early Release 10.1200/JCO.2005.04.1384 on December 27 2005

This Article Abstract Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lee, J. Articles by Kim, W. S. Search for Related Content PubMed PubMed Citation Articles by Lee, J. Articles by Kim, W. S.

Extranodal Natural Killer T-Cell Lymphoma, Nasal-Type: A Prognostic Model From a Retrospective Multicenter Study

From the Division of Hematology-Oncology, Department of Medicine, Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine; Division of Hematology-Oncology, Department of Diagnostic Pathology, Asan Medical Center, University of Ulsan College of Medicine; Department of Hematology-Oncology, Korea Cancer Center Hospital; Department of Hematology-Oncology, Dankook University School of Medicine; Department of Internal Medicine, College of Medicine, Hallym University, Seoul, Korea; Department of Hematology-Oncology, Gachun Medical School Gil Medical Center, Incheon; Research Institute & Hospital, National Cancer Center, Goyang, Gyeonggi; Dong-A Cancer Center, Dong-A University College of Medicine, Busan; Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul Department of Medicine, Cheju National University College of Medicine, Jeju, Korea

Address reprint requests to Won Seog Kim, MD, PhD, Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon-dong Kangnam-ku, Seoul 135-710 Korea; e-mail: wskimsmc{at}smc.samsung.co.kr OR wskimsmc{at}hanmail.net

	ABSTRACT

TOP ABSTRACT INTRODUCTION PATIENTS AND METHODS RESULTS DISCUSSION Authors' Disclosures of... Author Contributions REFERENCES

 
PURPOSE: Patients with natural killer T (NK/T) -cell lymphomas have poor survival outcome, and for this condition there is no optimal therapy. The purpose of this study was to design a prognostic model specifically for extranodal NK/T-cell lymphoma, which can identify high-risk patients who need more aggressive therapy.

PATIENTS AND METHODS: This multicenter retrospective study was comprised of 262 patients who were diagnosed with NK/T-cell lymphoma.

RESULTS: After a median follow-up duration of 51.2 months, 5-year overall survival rate in 262 patients was 49.5%. Prognostic factors for survival were "B" symptoms (P = .0003; relative risk, 2.202; 95% CI, 1.446 to 3.353), stage (P = .0006; relative risk, 2.366; 95% CI, 1.462 to 3.828), lactate dehydrogenase (LDH) level (P = .0005; relative risk, 2.278; 95% CI, 1.442 to 3.598), and regional lymph nodes (P = .0044; relative risk, 1.546; 95% CI, 1.009 to 2.367). Of 262 patients, 219 had complete information on four parameters. We identified four different risk groups: group 1, no adverse factor; group 2, one factor; group 3, two factors; and group 4, three or four factors. The new model showed a superior prognostic discrimination as compared with the International Prognostic Index (IPI). Notably, the distribution of patients was balanced when a new model was adopted (group 1, 27%; group 2, 31%; group 3, 20%; group 4, 22%), whereas 81% of patients were categorized as low or low-intermediate risks using IPI.

CONCLUSION: The newly proposed model for extranodal NK/T-cell lymphoma demonstrated a more balanced distribution of patients into four groups with better prognostic discrimination as compared with the IPI.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION PATIENTS AND METHODS RESULTS DISCUSSION Authors' Disclosures of... Author Contributions REFERENCES

 
Extranodal natural killer T (NK/T) -cell lymphoma, nasal-type, is a recently recognized distinct entity within the WHO classification of lymphoid tumors.¹ Not common in Western countries, extranodal NK/T-cell lymphoma is more common in Asia^2-9 accounting for 9% of all malignant lymphomas and 74% of lymphomas arising within nasal cavity and paranasal sinuses in Korea.¹⁰ Whereas most of sinonasal lymphomas are diffuse large B-cell lymphomas in Western population, 40% to 74% of sinonasal lymphomas are NK/T-cell lymphomas in Asia.^10,11 Au et al recently reported that the high incidence of mature T-cell and natural killer (NK) -cell lymphomas in China is due to a high frequency of NK-cell, but not T-cell lymphomas.¹¹ NK/T-cell lymphomas usually occur in middle-age patients, and their presenting features are characterized by a localized disease in about two thirds of the patients, frequent adjacent tissue invasion, a high frequency of "B" symptoms despite apparently limited disease, and rare bone marrow (BM) involvement.^12-14 They are also characterized by predominantly involving extranodal sites rendering the prefix extranodal NK/T-cell lymphoma in the WHO classification.

Because extranodal NK/T-cell lymphoma, nasal type is a relatively, newly recognized distinctive clinicopathologic entity in the WHO classification,^1,14,15 optimal treatment strategies and prognoses have not been fully defined yet. At a consensus meeting in 1997, the importance of clinical features and location of the primary lesion was emphasized in determining the biologic behavior and definition of the disease.¹⁶ We, and a few other groups, have demonstrated that patients with NK/T-cell lymphomas have poor survival outcome, with the cumulative probability of survival at 5 years ranging from 37.9% to 45.3%.^13,14,17 From radiotherapy alone to high-dose therapy with stem cell transplantation, several treatment options have been proposed for patients with extranodal nasal-type NK/T-cell lymphoma. Although validated in many lymphomas ranging from low to high grades, the prognostic impact of the International Prognostic Index (IPI) has been controversial in NK/T-cell lymphomas, with one previous study yielding positive correlations¹⁴ and four yielding negative correlations.^17-20 When using the IPI, a small proportion (0% to 7%) of NK/T-cell lymphoma patients is categorized as high-risk group.^12-14,18,20 Moreover, we have recently reported that two subtypes, namely upper aerodigestive tract NK/T-cell lymphoma (UNKTL) and extra-upper aerodigestive tract NK/T-cell lymphoma (EUNKTL), behave significantly different in regards to survival and prognosis.^13,21 In retrospective analyses of a series of NK/T-cell lymphomas, several variables were associated with poor survival, such as regional lymph node involvement,²⁰ elevated lactate dehydrogenase (LDH),^13,20 poor performance,¹³ paranasal extension,^20,22-24 the presence of B symptoms,^13,22,25 and high Epstein-Barr virus (EBV) DNA titer.²⁶ To design a prognostic model specifically for extranodal NK/T-cell lymphoma, we started a large, retrospective, multicenter study.

	PATIENTS AND METHODS

TOP ABSTRACT INTRODUCTION PATIENTS AND METHODS RESULTS DISCUSSION Authors' Disclosures of... Author Contributions REFERENCES

 
Patients
The criteria for case inclusion were as follows: (1) pathologically confirmed diagnosis of NK/T-cell lymphoma, according to the WHO classification; and (2) proven NK/T cell type by immunohistochemistry, flow cytometry, or EBV in situ hybridization. If EBV in situ hybridization was negative, patients were excluded from the analysis. Blastic NK-cell lymphoma/leukemia, aggressive NK-cell lymphoma/leukemia, and peripheral T-cell lymphoma, unspecified were excluded from the analysis. Two subtypes of extranodal NK/T-cell lymphoma, UNKTL and EUNKTL, were defined as previously described. Briefly, UNKTL includes all lymphomas confined to nasal cavity, nasopharynx, and the upper aerodigestive tract, whereas EUNKTL embraces lymphomas occurring at all other sites. Patients with primary lesion within the nasal cavity and secondary spread to other organs were categorized as UNKTL. (3) A complete set of clinical information was the third criterium. Patients with the following clinical data were considered eligible: patient demographics, complete blood count, Ann Arbor stage, computed tomography (CT) scan or magnetic resonance imaging (MRI) scan of the involved region, CT scan of abdomen, and BM findings. All patients provided informed consent in compliance with institutional guidelines.

Local invasiveness was defined differently according to the two subtypes. For UNKTL, local invasiveness was defined in accordance with 2002 TNM classification of the American Joint Committee on Cancer: T1 tumor restricted to any one subsite, with or without bony invasion; T2 tumor invading two subsites in a single region or extending to involve an adjacent region within the nasoethmoidal complex, with or without bony invasion; T3 tumor extends to invade the medial wall or floor of the orbit, maxillary sinus, palate, or cribriform plate; T4 tumor invades any of the following: anterior orbital contents, skin of nose or cheek, minimal extension to anterior cranial fossa, pterygoid plates, sphenoidal or frontal sinuses, orbital apex, dura, brain, middle cranial fossa, nasopharynx, or clivus. Any UNKTL with T3 or greater were considered as local invasiveness in the analysis. For EUNKTL, the definition of local invasiveness differed according to primary sites. For gastrointestinal EUNKTL, local invasiveness referred to T4 lesion in TNM system. In EUNKTL primarily involving soft tissue, such as muscle or skin, invasion of neurovascular structure or bone invasion was considered as local invasion. Regional lymphadenopathies were defined as the invasion of lymph nodes corresponding to N1, N2, or N3 of the primary lesion at TNM staging system. Accordingly, M1 nodes at TNM system were not categorized as regional lymph nodes in the analysis. B symptoms were defined as unexplained fever with temperature above 38°C, night sweats, and unexplained weight loss of more than 10% of the usual body weight in the 6 months before diagnosis.

From 1991 to 2004, 304 patients were accrued from 10 tertiary hospitals in Korea. Of 304 patients, we excluded 42 patients for the following reasons: 12 patients did not have sufficient clinical data available at the time of analysis; 13 patients showed EBV negativity for in situ hybridization; five patients had NK/T cell leukemia; four patients had blastic NK lymphoma/leukemia; three patients had peripheral T-cell lymphoma unspecified; and five patients for other reasons, such as inadequate quality of pathologic specimen for definitive diagnosis.

Histology
All pathologic specimens were reviewed and reclassified by central review in accordance with the WHO criteria for pathologic diagnosis.¹ Immunophenotyping was performed using a panel of monoclonal antibodies, including antibodies against cytoplasmic CD3 (Dakopatts, Copenhagen, Denmark), CD20 (Dakopatts), and CD56 (Monosan, Uden, the Netherlands). EBV RNA was detected by an in situ hybridization technique. Briefly, paraffin sections were pretreated with xylene, followed by treatment with proteinases K and hybridized with fluorescein isothiocyanate-conjugated EBV oligonucleotides (Dakopatts) complementary to the nuclear RNA portion of the EBER1 and EBER2 genes.

Treatment
Patients received one of the following initial treatment modalities: (1) an anthracycline-containing chemotherapeutic regimen followed by radiotherapy (RT); (2) a non–anthracycline-containing chemotherapeutic regimen followed by RT; (3) anthracycline-based chemotherapy; (4) non–anthracycline-based chemotherapy; (5) involved-field RT as the primary treatment; (6) surgery alone; and (7) supportive care only. The anthracycline-based regimens used were as following: cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP); dose-escalated CHOP (deCHOP); cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, procarbazine (COPBLAM); and (etoposide, doxorubicin, vincristine, cyclophosphamide, prednisolone (EPOCH). The non–anthracycline-containing regimens used were ifosfamide, methotrexate, etoposide (IMEP); dexamethasone, ifosfamide, cisplatin, etoposide (DICE); etoposide, methylprednisolone, cisplatin, cytarabine (ESHAP); dexamethasone, cytarabine, cisplatin (DHAP); etoposide, ifosfamide, cisplatin, dexamethasone (VIPD); and cyclophosphamide, vincristine, prednisone (CVP). In patients with localized disease, involved-field radiotherapy was given at the physician's discretion following chemotherapy. The treatment response was assessed according to standard response criteria.²⁷

Statistical Analysis
Overall survival (OS) and relapse-free survival (RFS) were estimated using the Kaplan-Meier product-limit method. OS was measured from the date of diagnosis to the date of death or the last follow-up visit. RFS was calculated from the date of diagnosis to the first documented relapse in patients who attained complete remission (CR). Survival rates were compared for statistical differences by using log-rank analysis. Continuous biologic variables were dichotomized. A prognostic model was established by fitting all variables that significantly influenced OS at a level of P = .05 in the univariate analysis. A forward stepwise Cox regression analysis²⁸ was then performed and prognostic index was derived. P = .05 were considered statistically significant and all P values correspond to two-sided significance tests.

	RESULTS

TOP ABSTRACT INTRODUCTION PATIENTS AND METHODS RESULTS DISCUSSION Authors' Disclosures of... Author Contributions REFERENCES

 
Patient Characteristics
In all, 262 patients from 10 centers fulfilled the inclusion criteria and were registered for the study. The clinical characteristics of the 262 patients are outlined in Table 1. The majority of the patients were categorized as UNKTL (222 of 262, 85%). EUNTKLs (40 of 262, 15%) included primary lesions at the following sites: soft tissue (n = 10), gastrointestinal tract (n = 10), skin (n = 7), liver (n = 4), lung (n = 4), orbit (n = 2), and other (n = 3). The IPI scores were distributed as 212 of 262 patients (81%) had IPI scores between 0 to 2, and 41 patients (19%) had IPI scores between 3 or 4.

View larger version (9K): [in this window] [in a new window]   Fig 1. Survival of 262 natural killer T-cell lymphoma patients. OS, overall survival.

View larger version (15K): [in this window] [in a new window]   Fig 2. Survival according to localized or disseminated subtypes of natural killer T-cell lymphoma. OS, overall survival; UNKTL, upper aerodigestive tract natural killer T-cell lymphoma; EUNKTL, extra upper aerodigestive tract natural killer T-cell lymphoma.

Prognostic Model
Clinical parameters that were included in the multivariate analysis were Eastern Cooperative Oncology Group performance status, stage, LDH, subtypes, regional lymphadenopathy, local invasiveness, B symptoms, and BM involvement. The forward conditional Cox regression model was used. Prognostic factors for survival were B symptoms (P = .0003; relative risk, 2.202; 95% CI, 1.446 to 3.353), stage (P = .0006; relative risk, 2.366; 95% CI, 1.462 to 3.828), LDH level (P = .0005; relative risk, 2.278; 95% CI, 1.442 to 3.598), and regional lymph nodes (P = .0044; relative risk, 1.546; 95% CI, 1.009 to 2.367). Of 262 patients, 219 patients had complete information on four parameters and thus included in the prognostication. The prognostic grouping of the 219 patients was performed according to the following criteria: group 1, no adverse factors; group 2, one factor; group 3, two factors; and group 4, three or four factors. The survival curves according to the new prognostic index for NK/T-cell lymphomas are shown in Figure 3. The new index categorized four groups with significantly different survival outcomes (P < .0001). The proportion of patients in each group and associated hazard ratios are presented in Table 2. Of 219 patients, 215 patients had complete information available for the parameters of the IPI. The IPI separated the patients into four risk groups with different survival outcomes (Fig 4). However, the IPI did not discriminate well between the low and low-intermediate risk groups (P = .0614) or between the high-intermediate and high risk groups (P = .8304). As shown in Figure 5, the new prognostic model was efficient in discriminating the patients with low to low-intermediate risk according to the IPI (P = <.0001). The model differentiated high-intermediate risk group (n = 4) from high-risk patients (n = 4) according to the IPI, with borderline significance (P = .0742).

View larger version (13K): [in this window] [in a new window]   Fig 3. Survival according to the new prognostic index. Group 1, n = 60 (27%); group 2, n = 68 (31%); group 3, n = 44 (20%); group 4, n = 47 (22%). OS, overall survival.

View larger version (13K): [in this window] [in a new window]   Fig 4. Survival according to IPI. Low risk, n = 148 (69%); low-intermediate risk, n = 34 (16%); high-intermediate risk, n = 19 (9%); high risk, n = 14 (7%). OS, overall survival.

View larger version (11K): [in this window] [in a new window]   Fig 5. Overall survival (OS) of patients with low to low-intermediate International Prognostic Index (IPI) risk, and those with high-intermediate to high IPI risk as determined by the new prognostic model. (A) Low to low-intermediate IPI risk: group 1, n = 60 (33%); group 2, n = 68 (37%); group 3, n = 40 (22%); group 4, n = 14 (8%); (B) high-intermediate to high IPI risk: group 3, n = 4 (12%); group 4, n = 29 (88%).

	DISCUSSION

TOP ABSTRACT INTRODUCTION PATIENTS AND METHODS RESULTS DISCUSSION Authors' Disclosures of... Author Contributions REFERENCES

Although this subset of lymphomas is known for its poor prognosis (5-year OS rate, 49.5%, Fig 1), 81% of the patients had IPI scores less than 2 (Table 1). Furthermore, the IPI did not distinguish between low-risk and low-intermediate-risk groups with sufficient statistical power (P = .0614). This may be partly explained by peculiar clinical features of the disease such as high frequency of localized disease (76%), rare involvement of BM (6%), and high occurrence of constitutional symptoms in localized disease (29%). BM involvement is markedly low in NK/T-cell lymphomas as compared to PTCLu (20% to 40%).³¹ In our analysis, performance status, stage, LDH, EUNKTL subtype, regional lymphadenopathies, local invasiveness, B symptoms, and BM involvement were significant prognostic parameters for survival at univariate analysis (Table 3). However, only four factors, B symptoms, stage, LDH, and regional lymph node invasion were retained at a multivariate level (Table 4). Various treatment modalities were not included in the prognostic analysis since the aim of the model was to identify risk groups from initial clinical variables to aid in determining therapeutic approach. Notably, the distribution of patients was balanced when a new model was adopted (group 1, 27%; group 2, 31%; group 3, 20%; group 4, 22%; Table 5) .

Few groups have suggested that local invasiveness, such as paranasal extension, is an important adverse factor for survival in nasal NK/T-cell lymphomas.^20,22-24 Kim et al has analyzed the prognostic significance of local tumor invasiveness in 114 stage I/II nasal NK/ T-cell lymphoma patients and demonstrated that the presence of local tumor invasiveness was a significant adverse factor for CR, disease-free survival, or OS.³³ Local tumor invasiveness was defined as bony invasion and/or perforation or invasion of the skin based on CT and physical findings in their study. However, in our analysis, statistical significance of local invasiveness shown at univariate level was not maintained at multivariate analysis. Although there was a significant survival difference according to local invasiveness in patients without lymph node invasion (P = .0234, Fig 6A), the survival difference was abrogated in patients with lymph node invasion (P = .8482, Fig 6B). Therefore, invasion of regional lymph nodes may be a more powerful predictive factor for poor survival outcome than local tumor invasiveness.

View larger version (11K): [in this window] [in a new window]   Fig 6. Subgroup analysis of patients according to local invasiveness and regional lymph node invasions. (A) Survival in lymph node-negative patients according to local invasiveness; (B) survival in lymph node-positive patients according to local invasiveness. OS, overall survival.

	Authors' Disclosures of Potential Conflicts of Interest

TOP ABSTRACT INTRODUCTION PATIENTS AND METHODS RESULTS DISCUSSION Authors' Disclosures of... Author Contributions REFERENCES

 
The authors indicated no potential conflicts of interest.

	Author Contributions

TOP ABSTRACT INTRODUCTION PATIENTS AND METHODS RESULTS DISCUSSION Authors' Disclosures of... Author Contributions REFERENCES

 

Conception and design: Jeeyun Lee, Cheolwon Suh, Young H. Ko, Won Seog Kim Collection and assembly of data: Jeeyun Lee, Yeon Hee Park, Young H. Ko, Soo Mee Bang, Jae Hoon Lee, Dae Ho Lee, Jooryung Huh, Sung Yong Oh, Hyuk-Chan Kwon, Hyo Jin Kim, Soon Il Lee, Jung Han Kim, Jinny Park, Seok Joong Oh, Kihyun Kim, Chulwon Jung, Keunchil Park, Won Seog Kim Data analysis and interpretation: Jeeyun Lee, Yeon Hee Park, Soo Mee Bang, Won Seog Kim Manuscript writing: Jeeyun Lee, Cheolwon Suh Final approval of manuscript: Jeeyun Lee, Cheolwon Suh, Yeon Hee Park, Keunchil Park, Won Seog Kim

 

	NOTES

 
J.L., C.S., and Y.H.P. contributed equally to the work presented here.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

	REFERENCES

TOP ABSTRACT INTRODUCTION PATIENTS AND METHODS RESULTS DISCUSSION Authors' Disclosures of... Author Contributions REFERENCES

 
1. Jaffe ES, Harris NL, Stein H, et al: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Hematopoietic and Lymphoid Tissues. Lyon, Frances, IARC Press, 2001, pp 204-207

2. Aozasa K, Ohsawa M, Tajima K, et al: Nationwide study of lethal mid-line granuloma in Japan: Frequencies of Wegener's granulomatosis, polymorphic reticulosis, malignant lymphoma and other related conditions. Int J Cancer 44:63-66, 1989[Medline]

3. Chan JKC, Ng CS, Lau WH, et al: Most nasal/nasopharyngeal lymphomas are peripheral T-cell neoplasms. Am J Surg Pathol 11:418-429, 1987[Medline]

4. Ferry J, Sklar J, Zukerberg L, et al: Nasal lymphoma: A clinicopathologic study with immunophenotypic and genotypic analysis. Am J Surg Pathol 15:268-779, 1991[Medline]

5. Harabuchi Y, Yamanaka N, Kataura A, et al: Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet 335:128-130, 1990[CrossRef][Medline]

6. Ho FCS, Choy D, Loke SL, et al: Polymorphic reticulosis and conventional lymphomas of the nose and upper aerodigestive tract: A clinicopathologic study of 70 cases, and immunophenotypic studies of 16 cases. Hum Pathol 21:1041-1050, 1990[CrossRef][Medline]

7. Liang R, Todd D, Chan TK, et al: Treatment outcome and prognostic factors for primary nasal lymphoma. J Clin Oncol 13:666-670, 1995[Abstract/Free Full Text]

8. Kim GE, Cho JH, Yang WI, et al: Angiocentric lymphoma of the head and neck: Patterns of systemic failure after radiation treatment. J Clin Oncol 18:54-63, 2000[Abstract/Free Full Text]

9. Siu LL, Chan JK, Kwong YL: Natural killer cell malignancies: Clinicopathologic and molecular features. Histol Histopathol 17:539-554, 2002[Medline]

10. Ko YH, Kim CW, Park CS, et al: REAL classification of malignant lymphomas in the Republic of Korea: Incidence of recently recognized entities and changes in clinicopathologic features. Cancer 83:806-812, 1998[CrossRef][Medline]

11. Au WY, Ma SY, Chim CS, et al: Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: A single center experience of 10 years. Ann Oncol 16:206-214, 2005[Abstract/Free Full Text]

12. Kim K, Kim WS, Jung CW, et al: Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification. Eur J Cancer 38:75-81, 2002[Medline]

13. Lee J, Park YH, Kim WS, et al: Extranodal nasal type NK/T-cell lymphoma: Elucidating clinical prognostic factors for risk-based stratification of therapy. Eur J Cancer 41:1402-1408, 2005[CrossRef][Medline]

14. Chim CS, Ma SY, Au WY, et al: Primary nasal natural killer cell lymphoma: Long-term treatment outcome and relationship with the International Prognostic Index. Blood 103:216-221, 2004[Abstract/Free Full Text]

15. Jaffe ES: Classification of natural killer (NK) cell and NK-like T-cell malignancies. Blood 87:1207-1210, 1996[Free Full Text]

16. Harris NL, Jaffe ES, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the clinical advisory committee meeting- Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849, 1999[Abstract/Free Full Text]

17. Cheung MM, Chan J, Lai W, et al: Early stage nasal NK/T-cell lymphoma: Clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 54:182-190, 2002[Medline]

18. Cheung MM, Chan J, Lau W, et al: Primary non-Hodgkin's lymphoma of the nose and nasopharynx: Clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 16:70-77, 1998[Abstract/Free Full Text]

19. Aviles A, Diaz NR, Neri N, et al: Angiocentric nasal T/natural killer cell lymphoma: A single centre study of prognostic factors in 108 patients. Clin Lab Haematol 22:215-220, 2000[CrossRef][Medline]

20. You JY, Chi KH, Yang MH, et al: Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: A single institute survey in Taiwan. Ann Oncol 15:618-625, 2004[Abstract/Free Full Text]

21. Lee J, Kim WS, Park YH, et al: Nasal-type NK/T-cell lymphoma: Clinical features and treatment outcome. Br J Cancer 92:1226-1230, 2005[CrossRef][Medline]

22. Robbins KT, Fuller LM, Vlasak M, et al: Primary lymphomas of the nasal cavity and paranasal sinuses. Cancer 56:814-819, 1985[CrossRef][Medline]

23. Logsdon MD, Ha CS, Kavadi VS, et al: Lymphoma of the nasal cavity and paranasal sinuses: Improved outcome and altered prognostic factors with combined modality therapy. Cancer 80:477-488, 1997[CrossRef][Medline]

24. Li YX, Coucke PA, Li JY, et al: Primary non-Hodgkin's lymphoma of the nasal cavity: Prognostic significance of paranasal extension and the role of radiotherapy and chemotherapy. Cancer 83:449-456, 1998[CrossRef][Medline]

25. Kim WS, Song SY, Ahn YC, et al: CHOP followed by involved field radiation: Is it optimal for localized nasal natural killer/T-cell lymphoma? Ann Oncol 12:349-352, 2001[Abstract/Free Full Text]

26. Au WY, Pang A, Choy C, et al: Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood 104:243-249, 2004[Abstract/Free Full Text]

27. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol 17:1244-1253, 1999[Abstract/Free Full Text]

28. Cox DR: Regression models and life-tables. J Stat Soc 34:187-220, 1982

29. Gallamini A, Stelitano C, Calvi R, et al: Peripheral T-cell lymphoma unspecified (PTCL-U): A new prognostic model from a retrospective multicentric clinical study. Blood 103:2474-2479, 2004[Abstract/Free Full Text]

30. Solal-Céligny P, Roy P, Colombat P, et al: Follicular lymphoma international prognostic index. Blood 104:1258-1265, 2004[Abstract/Free Full Text]

31. Hanson CA, Brunning RD, Gajl-Peczalska KJ, et al: Bone marrow manifestation of peripheral T-cell lymphoma: A study of 30 cases. Am J Clin Pathol 86:449-460, 1986[Medline]

32. Au WY, Lie AKW, Liang R, et al: Autologous stem cell transplantation for nasal NK/T-cell lymphoma: A progress report on its value. Ann Oncol 14:1673-1679, 2003[Abstract/Free Full Text]

33. Kim TM, Park YH, Lee SY, et al: Local tumor invasiveness is more predictive of survival than international prognostic index in stage I_E/II_E extranodal NK/T-cell lymphoma, nasal type. Blood 106:3785-3790, 2005[Abstract/Free Full Text]

Submitted September 4, 2005; accepted November 8, 2005.

This article has been cited by other articles:

				J. Lee, C. Suh, H. J. Kang, B.-Y. Ryoo, J. Huh, Y. H. Ko, H.-S. Eom, K. Kim, K. Park, and W. S. Kim Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma Ann. Onc., December 1, 2008; 19(12): 2079 - 2083. [Abstract] [Full Text] [PDF]

				C. Suh, Y.-K. Kang, J.-L. Roh, M. R. Kim, J. S. Kim, J. Huh, J. H. Lee, Y. J. Jang, and B.-J. Lee Prognostic Value of Tumor 18F-FDG Uptake in Patients with Untreated Extranodal Natural Killer/T-Cell Lymphomas of the Head and Neck J. Nucl. Med., November 1, 2008; 49(11): 1783 - 1789. [Abstract] [Full Text] [PDF]

				Y.-X. Li, H. Fang, Q.-F. Liu, J. Lu, S.-N. Qi, H. Wang, J. Jin, W.-H. Wang, Y.-P. Liu, Y.-W. Song, et al. Clinical features and treatment outcome of nasal-type NK/T-cell lymphoma of Waldeyer ring Blood, October 15, 2008; 112(8): 3057 - 3064. [Abstract] [Full Text] [PDF]

				International T-Cell Lymphoma Project International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes J. Clin. Oncol., September 1, 2008; 26(25): 4124 - 4130. [Abstract] [Full Text] [PDF]

				T. M. Kim, S. -Y. Lee, Y. K. Jeon, B. -Y. Ryoo, G. J. Cho, Y. S. Hong, H. J. Kim, S.-Y. Kim, C. S. Kim, S. Kim, et al. Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group Ann. Onc., August 1, 2008; 19(8): 1477 - 1484. [Abstract] [Full Text] [PDF]

				K. J. Savage Prognosis and Primary Therapy in Peripheral T-Cell Lymphomas Hematology, January 1, 2008; 2008(1): 280 - 288. [Abstract] [Full Text] [PDF]

				S. Kim, B. Kim, C. Choi, J Choi, I Kim, Y-H Lee, and J. Kim Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type Ann. Onc., August 1, 2007; 18(8): 1382 - 1387. [Abstract] [Full Text] [PDF]

				J. Lee, C. Suh, J. Huh, H. J. Jun, K. Kim, C. Jung, K. Park, Y. H. Park, Y. H. Ko, and W. S. Kim Effect of Positive Bone Marrow EBV In situ Hybridization in Staging and Survival of Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal-Type Clin. Cancer Res., June 1, 2007; 13(11): 3250 - 3254. [Abstract] [Full Text] [PDF]

				C. Bossard, K. Belhadj, F. Reyes, N. Martin-Garcia, F. Berger, J. A. Kummer, J. Briere, A.-C. Baglin, S. Cheze, J. Bosq, et al. Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials Blood, March 1, 2007; 109(5): 2183 - 2189. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lee, J. Articles by Kim, W. S. Search for Related Content PubMed PubMed Citation Articles by Lee, J. Articles by Kim, W. S.